SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Sunshine Biopharma, Inc. SBFMW NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Sunshine Biopharma, Inc. (SBFMW) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.14. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Valuation: SBFMW trades at a trailing Price-to-Earnings (P/E) of -0.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.

Financials: revenue is $36M, +167.7%/yr average growth. Net income is $6M (loss), growing at +17.6%/yr. Net profit margin is -16.5% (negative). Gross margin is 33.8% (-5.2 pp trend).

Balance sheet: total debt is $0 against $23M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 4.17 (strong liquidity). Debt-to-assets is 0%. Total assets: $3M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 21/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

SBFMW SharesGrow Score Overview

64/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 90/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 21/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SBFMW

SBFMW trades at a trailing Price-to-Earnings (P/E) of -0.7 (S&P 500 average ~25). Forward PEG 0.01 — Peter Lynch undervalued (≤1.0). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

SBFMW: +167.7%/yr revenue is, +17.6%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet SBFMW: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 4.17 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

SBFMW: Gross margin is 33.8% (-5.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

SBFMW: Net profit margin is -16.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.0851-0.299

Volume300

Avg Volume (30D)2.72K

Market Cap$681.93K

Beta (1Y)1.60

Share Statistics

EPS (TTM)-1.44

Shares Outstanding$4.16M

IPO Date2022-02-15

Employees52

CEOSteve N. Slilaty

Financial Highlights & Ratios

Revenue (TTM)$36.31M

Gross Profit$12.26M

EBITDA$-5.62M

Net Income$-5.98M

Operating Income$-6.23M

Total Cash$9.12M

Net Debt$-9.12M

Total Assets$3.23M

Price / Earnings (P/E)-0.1

Price / Sales (P/S)0.02

Analyst Forecast

Company Info

CountryCA

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS8677815024

Price Chart

SBFMW

Sunshine Biopharma, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Drug Manufacturers - Specialty & Generic

0.09 52WK RANGE 0.30

People Also View

NeuroSense Therapeutics Ltd.

Sunshine Biopharma, Inc.

MedAvail Holdings, Inc.

Biofrontera Inc.

Inspirato Incorporated

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message